Business News • PR NewsWire • Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology

Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology

Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Ann

View More : http://www.prnewswire.com/news-releases/ardea-biosciences-provides-additional-results-from-a-phase-2b-study-of-lesinurad...

Releted News by prnewswire

CreditCards.com: Weekly Credit Card Rate Report

MFA Financial, Inc. to Present at the Keefe, Bruyette & Woods 2011 Investment Management & Specialty Finance Conference and at the Deutsche Bank Securities Inc. 2011 Global Financial Services Investor Conference